Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Truist Securities Downgrades Aerie Pharmaceuticals to Hold

Truist Securities Downgrades Aerie Pharmaceuticals to Hold

Truist Securities analyst Gregory Fraser downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Hold.

byBenzinga Newsdesk

August 24, 2022

1 minute read

Truist Securities analyst Gregory Fraser downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Hold.

Evercore ISI Group Maintains Outperform on Noble Corp, Raises Price Target to $53

By Benzinga Newsdesk

February 28, 10:25 AM

Evercore ISI Group analyst James West maintains Noble Corp (NYSE:NE) with a Outperform and raises the price target from $49 to $53.

Analyst Ratings

Analyst Ratings for First Bancorp

By Benzinga Insights

October 6, 3:30 PM

Analysts have provided the following ratings for First Bancorp (NASDAQ:FBNC) within the last quarter:

FBNC

$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,800 Today

By Benzinga Insights

June 27, 12:30 PM

Intercontinental Exchange (NYSE:ICE) has outperformed the market over the past 15 years by 2.89% on an annualized basis…

ICE

Illumina’s Grail Acquisition Gains Support from GOP Lawmakers and Advocacy Groups Despite FTC Resistance

By Vandana Singh

June 14, 12:15 PM

Republican lawmakers, state attorneys general, and several advocacy groups have expressed their support for Illumina Inc's (NASDAQ: ILMN) acquisition of Grail Inc, even as the Federal Trade Commission (FTC) continues challenging the deal.

ILMN

Truist Securities Downgrades Aerie Pharmaceuticals to Hold

Related Posts

Evercore ISI Group Maintains Outperform on Noble Corp, Raises Price Target to $53

Analyst Ratings for First Bancorp

$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,800 Today

Illumina’s Grail Acquisition Gains Support from GOP Lawmakers and Advocacy Groups Despite FTC Resistance